Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
麥迪衛康健康醫療管理科技
Mediwelcome Healthcare Management & Technology
COMPANY PROFILE

Mediwelcome Healthcare Management & Technology is provider in the Integrated Healthcare Marketing Solutions Market in China.

It primarily provides (i) medical conference services, (ii) patient education and screening services, and (iii)marketing strategy and consulting services, and also began to offer CRO services in late 2019 which primarily consist of patients' recruitment and clinical data collection services, and internet hospital services which mainly provide online follow up consultation to the physicians' existing patients and e-prescription service.

To boost its patient education and screening capabilities, it developed and launched the Online Conference Assistant , a WeChat mini-program that assists physicians in organizing and managing onsite patient education classes, as well as various WeChat public accounts where patients can find self-management support through watching educational videos, reading disease-related educational articles and conducting disease risk screening. It also have launched the Conference+ App for users, i.e. medical NGOs and pharmaceutical companies, to submit onsite conference requests and monitor conference implementation.

Its integrated healthcare marketing solutions are principally provided to China's esteemed medical NGOs and well-known pharmaceutical companies, it also serves medical device companies, healthcare and pharmaceutical publications and hospitals. It have developed a network of approximately 24,000 CCVD physicians as of June 30, 2020, among which over 70% worked for Grade 3 hospitals in China.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Websitewww.mediwelcome.com
Board Lot800
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
GLOBAL OFFERING
No. of Offer Shares50.00m shares
No. of International Offer Shares45.00m shares
No. of HK Offer Shares5.00m shares
Offer Price$3.00 - $4.00
Nominal ValueHK$ 0.00001 each
Stock Code2159
Sole Sponsor and Sole Global CoordinatorCEB International Capital
Joint BookrunnersCEB International Capital, Aristo Securities, BOCOM International Securities, CMBC Securities, SPDB International Capital
Joint Lead managersCEB International Capital, Aristo Securities, BOCOM International Securities, CMBC Securities, Ruibang Securities, SPDB International Capital, Wonderland International Securities
TIME TABLE
Application PeriodDec 31 (Thu) - Noon, Jan 8 (Fri)
Price Determination DateOn or Before 5pm, Jan 8 (Fri)
Result Announcement DateOn or Before Jan 18 (Mon)
Dispatch of Shares and Refund ChequesOn or Before Jan 18 (Mon)
Dealings in Shares commence onJan 19, 2021. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
DIRECTORS
ExecutiveShi Wei (Chairman), Yang Weimin, Wang Liang, He Jiyong, Wang Wei, Sui Huijun
Non-ExecutiveZhang Yitao, Liu Xia
Independent Non-ExecutiveSong Ruilin, Xiang Fei John, Wang Zheng David, Yang Xiaoxi
MAJOR SHAREHOLDERS
Shi Wei 20.33%
Yang Weimin12.70%
Zhang Yitao12.70%
Wang Liang6.02%
INCOME STATEMENT (RMB'000)
(Year ended Dec 31)
2020 *20192018
Revenue138,681427,159298,968
Gross Profit28,13294,86884,596
Pre-Taxed Profit(4,568)25,97249,152
Attributable Profit for the period(2,278)20,85238,041
* For the six months ended June 30, 2020.
FY 2020 PROFIT FORECAST (RMB)
Attributable Profit (not less than)21m
Unaudited pro forma EPS11 cents
OFFER STATISTICS (HK$)
Offer Price$3.00 - $4.00
Capitalization$600m - $800m
Unaudited pro forma adj NAV / share$1.21 - $1.43
USE OF PROCEEDS
Assuming the offer price being at the mid-point of $3.50, the net proceeds raised would be HK$110.8m, of which:
* $64.3m (58.0%) use to broaden its customer base, disease area coverage and patient base ;
* $27.7m (25.0%) use to complement its service capabilities through the development of internet hospital services ;
* $13.3m (12.0%) use for its working capital and general corporate purposes;
* $5.5m (5.0%) use to further expand its CRO services.
RELATED STOCK COMPARISON
Code Name Nominal Change %Change
02159MEDIWELCOMEdown2.770-0.050-1.773%
09906HONLIV HEALTHunchange1.8200.0000.000%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 14/04/2021 11:01
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.